Coeptis Therapeutics, Inc. (COEP)
USD 0.18
(-16.07%)
USD 0.18
(-16.07%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2005 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.23 Million | -3.87 Million | -4.48 Million | -3.13 Million | -90.06 Thousand | -417.02 Thousand |
| Net Income | -21.26 Million | -37.57 Million | -13.44 Million | -9.15 Million | -2234.00 | -344.3 Thousand |
| Depreciation & Amortization | 1 Million | 1 Million | 447.41 Thousand | 323.42 Thousand | - | - |
| Deferred income taxes | -1.32 Million | - | 5.33 Million | - | - | - |
| Stock-based compensation | 477.5 Thousand | - | 1.89 Million | - | - | - |
| Change in working capital | 1.76 Million | -550.33 Thousand | -2.97 Million | 2.66 Million | 450.00 | -72.72 Thousand |
| Other non-cash items | 11.97 Million | 33.24 Million | 4.25 Million | 3.03 Million | -88.28 Thousand | - |
| Investing Cash Flow | - | - | -1.75 Million | -75.75 Million | - | - |
| Investments in PPE | 4.00 | - | -1.75 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -75.75 Million | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 4.91 Million | 5.48 Million | 8.21 Million | 2.89 Million | 90.57 Thousand | 570.2 Thousand |
| Debt repayment | -575 Thousand | -2.41 Million | -1.7 Million | -250 Thousand | -90.57 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -247.16 Thousand | - | - | - |
| Common Stock Issuance | 4.79 Million | 3.27 Million | 10.13 Million | 1.06 Million | - | 15.2 Thousand |
| Other Financing Activities | 700 Thousand | 4.63 Million | 104.29 Thousand | 2.08 Million | - | 555 Thousand |
| Accounts receivables | -30.9 Thousand | -8075.00 | 21.78 Thousand | -14.9 Thousand | - | - |
| Accounts payables | 1.32 Million | -35.07 Thousand | -1.57 Million | 1.47 Million | - | - |
| Inventory | - | - | -422.02 Thousand | 732.14 Thousand | - | - |
| Other working capital | 471.86 Thousand | -507.18 Thousand | -1 Million | 472.67 Thousand | 450.00 | -72.72 Thousand |
| Cash at beginning of period | 3.79 Million | 2.17 Million | 202.96 Thousand | 440.08 Thousand | - | 383.00 |
| Cash at end of period | 1.46 Million | 3.79 Million | 2.17 Million | 202.96 Thousand | 505.00 | 153.55 Thousand |
| Capital Expenditure | 4.00 | - | -1.75 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | 75.75 Million | - | - |
| Net cash flow / Change in cash | -2.32 Million | 1.61 Million | 1.97 Million | -237.12 Thousand | 505.00 | 153.17 Thousand |
| Free Cash Flow | -7.23 Million | -3.87 Million | -6.23 Million | -3.13 Million | -90.06 Thousand | -417.02 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.03 Million | -3 Million | -21.26 Million | -3.75 Million | -6.26 Million | -3.11 Million |
| Depreciation & Amortization | 250.21 Thousand | 250.21 Thousand | 1 Million | 250.3 Thousand | 250.3 Thousand | 250.3 Thousand |
| Deferred income taxes | - | - | -1.32 Million | 807.8 Thousand | -1.09 Million | 286.5 Thousand |
| Stock-based compensation | 611.57 Thousand | 96.88 Thousand | 477.5 Thousand | 128.51 Thousand | 113.3 Thousand | 113.3 Thousand |
| Change in working capital | -29.01 Thousand | 86.87 Thousand | 1.76 Million | 907.34 Thousand | 181.42 Thousand | 209.04 Thousand |
| Other non-cash items | 1.98 Million | 1.31 Million | 11.97 Million | 506.04 Thousand | 4.85 Million | 351 Thousand |
| Investing Cash Flow | - | -100 Thousand | - | - | 350 Thousand | -350 Thousand |
| Investments in PPE | 1.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -100 Thousand | - | - | 350 Thousand | -350 Thousand |
| Financing Cash Flow | 1.94 Million | 1.56 Million | 4.91 Million | 1.75 Million | -224.92 Thousand | 3.39 Million |
| Debt repayment | -200 Thousand | -1.06 Million | -575 Thousand | -200 Thousand | -374.99 Thousand | -349.58 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.69 Million | 500 Thousand | 4.79 Million | 1.75 Million | 500.07 Thousand | 3.04 Million |
| Other Financing Activities | 50 Thousand | 500 Thousand | 700 Thousand | 200 Thousand | -350 Thousand | 699.58 Thousand |
| Accounts receivables | -82.5 Thousand | - | -30.9 Thousand | -38.97 Thousand | -833.00 | - |
| Accounts payables | -84.74 Thousand | -53.8 Thousand | 1.32 Million | 937.69 Thousand | 86.77 Thousand | 152.77 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 55.72 Thousand | 140.67 Thousand | 471.86 Thousand | 8632.00 | 94.65 Thousand | 56.26 Thousand |
| Cash at beginning of period | 1.02 Million | 1.46 Million | 3.79 Million | 1.41 Million | 3.24 Million | 2.1 Million |
| Cash at end of period | 1.55 Million | 1.02 Million | 1.46 Million | 1.46 Million | 1.41 Million | 3.24 Million |
| Capital Expenditure | 1.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 525.83 Thousand | -439.89 Thousand | -2.32 Million | 57.62 Thousand | -1.83 Million | 1.13 Million |
| Free Cash Flow | -1.41 Million | -1.9 Million | -7.23 Million | -1.69 Million | -1.95 Million | -1.9 Million |
BBZA
ALGEV
2871
306200
002232
1723